AU2002227415A1 - Protection of neurons against glutamate-induced damage in glaucoma and other conditions - Google Patents

Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Info

Publication number
AU2002227415A1
AU2002227415A1 AU2002227415A AU2741502A AU2002227415A1 AU 2002227415 A1 AU2002227415 A1 AU 2002227415A1 AU 2002227415 A AU2002227415 A AU 2002227415A AU 2741502 A AU2741502 A AU 2741502A AU 2002227415 A1 AU2002227415 A1 AU 2002227415A1
Authority
AU
Australia
Prior art keywords
glaucoma
protection
conditions
induced damage
neurons against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002227415A
Inventor
George S. Ayoub
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002227415A1 publication Critical patent/AU2002227415A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002227415A 2000-12-15 2001-12-12 Protection of neurons against glutamate-induced damage in glaucoma and other conditions Abandoned AU2002227415A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25608500P 2000-12-15 2000-12-15
US60/256,085 2000-12-15
US10/012,938 2001-12-10
US10/012,938 US20020077322A1 (en) 2000-12-15 2001-12-10 Protection of neurons against glutamate-induced damage in glaucoma and other conditions
PCT/US2001/048848 WO2002047691A1 (en) 2000-12-15 2001-12-12 Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Publications (1)

Publication Number Publication Date
AU2002227415A1 true AU2002227415A1 (en) 2002-06-24

Family

ID=26684208

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002227415A Abandoned AU2002227415A1 (en) 2000-12-15 2001-12-12 Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Country Status (3)

Country Link
US (1) US20020077322A1 (en)
AU (1) AU2002227415A1 (en)
WO (1) WO2002047691A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE406867T1 (en) * 2001-07-18 2008-09-15 Unilever Nv COMPOSITIONS FOR THE TREATMENT OF HAIR AND/OR SCALP
TW200407110A (en) 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
WO2004103410A1 (en) * 2002-06-06 2004-12-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods compositions and articles of manufacture for modulating bone growth
US20070129441A1 (en) * 2003-05-06 2007-06-07 University Of North Texas Health Science Center At Fort Worth Protection of cells from adverse external or intrinsic effects, cellular degeneration and death by n-acylethanolamines
US20060142395A1 (en) * 2003-05-06 2006-06-29 University Of North Texas Health Science Center Modulation of intracellular calcium signaling by N-acylethanolamines
US7425540B2 (en) * 2004-03-30 2008-09-16 The Hospital For Sick Children Method for modification of NMDA receptors through inhibition of Src
US8003609B2 (en) 2004-03-30 2011-08-23 The Hospital For Sick Children Method for ameliorating pain by modification of NMDA receptors through inhibition of Src
US20050282902A1 (en) * 2004-06-22 2005-12-22 Allergan, Inc. Abnormal cannabidiols as agents for lowering intraocular pressure
EP1758566A2 (en) * 2004-06-22 2007-03-07 Pharmos Limited Use of cb2 receptors agonists for the treatment of huntington"s disease
DE102004039326A1 (en) * 2004-08-12 2006-02-16 Abbott Gmbh & Co. Kg Treatment of neurodegenerative diseases, specifically Alzheimer's disease and Down syndrome, uses a chemical/biological substance which inhibits fatty acid amide hydrolase without inhibiting cyclooxygenase-1 and/or 2
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
WO2007032962A2 (en) * 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
US20100004244A1 (en) * 2006-06-27 2010-01-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of cb2 receptor agonists for promoting neurogenesis
US20100029739A1 (en) * 2006-10-04 2010-02-04 Uno Jakob Weber Use of a combination of hypothermia inducing drugs
MX2009003469A (en) * 2006-10-04 2009-05-28 Neurokey As Use of hypothermia inducing drugs to treat ischemia.
US7781650B2 (en) * 2007-04-30 2010-08-24 Monsanto Technology Llc Plants and seeds of corn variety CV202909
CN108853509A (en) * 2018-05-03 2018-11-23 浙江大学 The treatment and pharmaceutical composition of depression

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0301628A3 (en) * 2000-06-22 2007-05-29 Pharmos Corp Novel non-psychotropic cannabinoids

Also Published As

Publication number Publication date
US20020077322A1 (en) 2002-06-20
WO2002047691A1 (en) 2002-06-20
WO2002047691A9 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
AU2002227415A1 (en) Protection of neurons against glutamate-induced damage in glaucoma and other conditions
AU5274000A (en) Prevention of regression in refractive keratoplasty
AU2640099A (en) Structure member excellent in water-repellency and manufacturing method thereof
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2002225849A1 (en) Distal protection and delivery system and method
AU5455200A (en) The use of encapsulated acid in acid fracturing treatments
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
AU1812001A (en) Cotton transcription factors and their uses
AU2001243219A1 (en) Methods of prevention and treatment of asthma, and allergic conditions
AU2001285280A1 (en) Pivotal and retractable armrest assembly
AU5601300A (en) Method and compositions for treating and preventing retinal damage
AU2002211717A1 (en) Stresscopins and their uses
AU4843500A (en) Destructible surfactants and uses thereof
AU2001265025A1 (en) Fluorinated copolymer surfactants and use thereof in aerosol compositions
AU1049000A (en) Wirelesss network and methods to be used therein
AU4834200A (en) Fatty acid-n-substituted indol-3-glyoxyl-amide compositions and uses thereof
AU2002213588A1 (en) Soluble cd1 compositions and uses thereof
AU2001229439A1 (en) Bioconjugates and uses thereof
AU6385600A (en) Interconnect assemblies and methods
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AU3732500A (en) Beclin and uses thereof
AU2590101A (en) Electronic component protection devices and methods
AU2002246521A1 (en) Topography-guided opthalmic ablation and eye-tracking
AU2001233086A1 (en) Ceramidase compositions and methods based thereon
AU2001262963A1 (en) Laminin 15 and uses thereof